Specialized Medical Company (4019.SR) — Cash flow
Operating, investing, and financing cash flow for Specialized Medical Company — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 273↑453.2% | 49↑9.7% | 45↑64.1% | 27↑83.8% | 15 | |
| Depreciation & Amortization | 93↑299.9% | 23↓0.4% | 23↓15.4% | 28↑0.9% | 27 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -46↓769.7% | 7↑126.3% | -26↑12.7% | -30↑66.2% | -88 | |
| Accounts Receivable | -62↓367.9% | 23↑197.6% | -24↑26.1% | -32↓7.0% | -30 | |
| Inventory | -4↓618.9% | 0.85↑154.0% | -2↓643.2% | -0.21↓117.4% | 1 | |
| Accounts Payable | 0.00↑100.0% | -3↓334.7% | 1↓68.5% | 4↑146.2% | -9 | |
| Other Working Capital | 21↑245.1% | -14↓627.1% | -2↓35.8% | -1↑97.2% | -50 | |
| Other Non-Cash Items | 3↓79.1% | 13↑54.2% | 9↓42.8% | 15↓19.3% | 19 | |
| Net Cash from Operating Activities | 323↑248.7% | 93↑81.5% | 51↑26.4% | 40↑250.7% | -27 | |
| Operating Cash Flow | 323↑248.7% | 93↑81.5% | 51↑26.4% | 40↑250.7% | -27 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -94↓276.8% | -25↓29.3% | -19↓19.9% | -16↑19.1% | -20 | |
| Capital Expenditure | -94↓276.8% | -25↓29.3% | -19↓19.9% | -16↑19.1% | -20 | |
| Acquisitions | 0.00↓100.0% | 0.25↑10.9% | 0.22↑1197.6% | 0.02↓67.0% | 0.05 | |
| Purchases of Investments | -7 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Sales & Maturities of Investments | 4 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash from Investing Activities | -98↓293.0% | -25↓29.5% | -19↓18.6% | -16↑18.9% | -20 | |
| Financing Activities | ||||||
| Net Debt Issuance | -104↓2280.6% | 5↑232.4% | -4↓75.4% | -2↓103.6% | 58 | |
| Long-Term Net Debt Issuance | 140↑1012.7% | -15↓71.2% | -9↓47.8% | -6↓147.6% | 13 | |
| Short-Term Net Debt Issuance | -244↓1314.6% | 20↑277.2% | 5↑33.6% | 4↓91.2% | 45 | |
| Net Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | 0.00↑100.0% | -53↓232.9% | -16↓20.2% | -13↓42.7% | -9 | |
| Common Dividends Paid | 0.00↑100.0% | -53↓232.9% | -16↓20.2% | -13↓42.7% | -9 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | 33↑548.4% | -7↓40.5% | -5↑17.8% | -6↑6.4% | -7 | |
| Net Cash from Financing Activities | -71↓27.1% | -56↓124.4% | -25↓14.2% | -22↓152.2% | 42 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 8 | |
| Net Change in Cash | 154↑1198.2% | 12↑71.3% | 7↑190.9% | 2↓30.1% | 3 | |
| Cash at Beginning of Period | 92↑627.2% | 13↑119.3% | 6↑70.3% | 3 | 0.00 | |
| Cash at End of Period | 247↑902.9% | 25↑93.2% | 13↑119.9% | 6↑69.8% | 3 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 228↑238.3% | 67↑113.6% | 32↑30.8% | 24↑151.7% | -47 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.